GO:0070324 thyroid hormone binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070324 thyroid hormone binding is a molecular function describing the binding of thyroxine (T4) or triiodothyronine (T3), the tyrosine-based hormones produced by the thyroid gland.
• Thyroid hormone binding is mediated by nuclear thyroid hormone receptors (TRα, TRβ), serum transport proteins (TBG, transthyretin, albumin), and intracellular carriers such as µ-crystallin.
• The binding event is the first step in thyroid hormone action, converting a circulating hormone into a transcriptional regulator of metabolism, development, and differentiation.
• Mutations in serum thyroid hormone-binding proteins cause inherited euthyroid hyperthyroxinemia or hypothyroxinemia, which can be misdiagnosed as thyroid disease.
• Resistance to thyroid hormone (RTH) is frequently caused by mutations in the thyroid hormone receptor beta gene (THRB) that impair T3 binding.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of thyroid hormone binding in health and disease.
Description
Thyroid hormone binding (GO:0070324) is the molecular function defined as binding to thyroxine (T4) or triiodothyronine (T3), tyrosine-based hormones produced by the thyroid gland. This function is essential for the transport, cellular uptake, and nuclear action of thyroid hormones, which regulate metabolism, growth, and development. The thyroid gland synthesizes T4 and T3 through iodination of thyroglobulin, and their subsequent release into the circulation depends on binding to carrier proteins and receptors. Researchers study thyroid hormone binding to understand how hormones are delivered to target tissues, how they activate nuclear receptors, and how mutations in binding proteins cause disease. The binding function is executed by a diverse set of proteins, including nuclear receptors (THRA, THRB), serum transport proteins (SERPINA7, TTR, ALB), and intracellular carriers such as CRYM. Because thyroid hormones influence nearly every tissue, defects in binding can lead to metabolic, neurological, and developmental disorders. This article provides a research-grade overview of GO:0070324, covering its mechanism, key genes, disease links, and modern CRISPR-based methods for functional studies.
thyroid hormone binding At A Glance
| GO ID | GO:0070324 |
|---|---|
| GO term | thyroid hormone binding |
| Ontology | molecular_function |
| Synonym | thyroxine binding, triiodothyronine binding |
| Major function | Binding to T4 or T3, enabling transport, cellular uptake, and nuclear receptor activation |
| Major proteins | THRA, THRB, SERPINA7, TTR, ALB, CRYM |
| Disease relevance | Resistance to thyroid hormone, inherited hyperthyroxinemia, metabolic disorders |
| Research methods | CRISPR knockout/knock-in, binding assays, structural biology, transcriptomics |
What Is GO:0070324?
GO:0070324 thyroid hormone binding is a molecular function term in the Gene Ontology that describes the selective interaction of a protein or macromolecule with thyroxine (T4) or triiodothyronine (T3). These hormones are tyrosine-derived molecules synthesized by the thyroid gland. The binding event can occur in the bloodstream, in the cytoplasm, or in the nucleus, and it is a prerequisite for hormone transport, cellular entry, and transcriptional regulation. The term includes both thyroxine binding and triiodothyronine binding as synonyms, reflecting the two major active forms of thyroid hormone.
Why Is thyroid hormone binding Important in Cell Biology?
Thyroid hormone binding is a central node in endocrine physiology because it determines the bioavailability and activity of T3 and T4 in every tissue. Without proper binding, hormones cannot be transported in blood, cannot enter cells efficiently, and cannot activate nuclear receptors to regulate gene expression. This function is therefore critical for normal development, metabolic homeostasis, and neurological function, and its disruption is linked to a spectrum of inherited and acquired diseases.
• Enables the transport of hydrophobic thyroid hormones through the aqueous bloodstream via carrier proteins such as TBG, transthyretin, and albumin.
• Facilitates cellular uptake of T4 and T3 through membrane transporters and intracellular binding proteins like µ-crystallin.
• Allows T3 to bind nuclear thyroid hormone receptors (TRα and TRβ), which then regulate target gene transcription.
• Mutations in serum binding proteins cause euthyroid hyperthyroxinemia or hypothyroxinemia, leading to diagnostic confusion.
• Impaired T3 binding by mutant TRβ is the molecular basis of resistance to thyroid hormone (RTH).
• Thyroid hormone binding influences energy expenditure, lipid metabolism, and thermogenesis.
• It is essential for normal brain development and growth, as thyroid hormones regulate neuronal differentiation and myelination.
• Binding proteins modulate the free hormone hypothesis, affecting the interpretation of thyroid function tests.
• MicroRNAs can regulate components of thyroid hormone action, adding another layer of control.
• CRISPR screens and targeted models can identify novel binding proteins and their physiological roles.
Molecular Mechanism of thyroid hormone binding
Hormone synthesis and release
In simple terms: The thyroid gland makes T4 and T3 and releases them into the blood.
Thyroid hormone biosynthesis begins with iodination of thyroglobulin tyrosine residues, forming monoiodotyrosine and diiodotyrosine, which couple to generate T4 and T3. These hormones are stored in colloid and released into the circulation upon stimulation by thyroid-stimulating hormone. Once in the bloodstream, they immediately bind to serum carrier proteins, which is the first manifestation of GO:0070324.
Serum transport protein binding
In simple terms: Carrier proteins in the blood grab thyroid hormones and carry them around the body.
The majority of T4 and T3 in circulation is bound to thyroxine-binding globulin (TBG, encoded by SERPINA7), transthyretin (TTR), and albumin (ALB). These proteins exhibit high affinity but limited capacity, and their binding maintains a stable pool of free hormone. Mutations in these proteins alter the distribution of T4 and T3, leading to inherited euthyroid hyperthyroxinemia or hypothyroxinemia. This binding is a classic example of GO:0070324 in the extracellular space.
Cellular uptake and intracellular binding
In simple terms: Hormones enter cells with the help of transporters and bind to proteins inside.
Thyroid hormones cross the plasma membrane via specific transporters, including monocarboxylate transporters (MCT8, MCT10) and organic anion transporting polypeptides (OATPs). Inside the cell, T4 can be converted to the more active T3 by deiodinases. Intracellular binding proteins such as µ-crystallin (CRYM) bind T3 and modulate its availability to the nucleus. This step ensures that the hormone reaches its nuclear receptors.
Nuclear receptor binding and transcriptional regulation
In simple terms: Inside the nucleus, T3 binds to receptors that turn genes on or off.
The nuclear thyroid hormone receptors TRα (THRA) and TRβ (THRB) bind T3 with high affinity via their ligand-binding domains. In the absence of ligand, these receptors repress transcription by recruiting corepressors; upon T3 binding, they undergo a conformational change that releases corepressors and recruits coactivators, activating target gene expression. Structural studies have revealed the precise atomic interactions that mediate T3 binding and receptor activation. Mutations that impair this binding cause resistance to thyroid hormone.
Regulation of binding by microRNAs and other factors
In simple terms: Small RNA molecules can fine-tune how much thyroid hormone binding protein is made.
MicroRNAs have been shown to regulate the expression of thyroid hormone receptors and other components of the thyroid hormone axis, thereby indirectly influencing thyroid hormone binding. This adds a post-transcriptional layer of control to GO:0070324. Additionally, post-translational modifications and ligand availability can affect binding affinity and specificity.
Key Genes Involved in GO:0070324 thyroid hormone binding
The following genes encode proteins that directly mediate or regulate thyroid hormone binding (GO:0070324).
| Gene | Major Role | Research Relevance |
|---|---|---|
| THRA | Nuclear thyroid hormone receptor alpha; binds T3 to regulate gene expression | Mediates thyroid hormone action in brain, bone, and heart; target for KO and point-mutation studies |
| THRB | Nuclear thyroid hormone receptor beta; binds T3 to regulate metabolism and development | Mutations cause resistance to thyroid hormone (RTH); key disease model |
| SERPINA7 | Thyroxine-binding globulin (TBG); major serum carrier of T4 and T3 | Mutations cause inherited TBG deficiency or excess; diagnostic marker |
| TTR | Transthyretin; serum and cerebrospinal fluid carrier of T4 | Mutations cause amyloidosis and altered thyroid hormone distribution |
| ALB | Albumin; low-affinity, high-capacity carrier of thyroid hormones | Modulates free hormone levels; relevant in liver disease |
| CRYM | µ-Crystallin; intracellular T3-binding protein | Regulates T3 availability; potential role in hearing and metabolism |
| DIO1 | Type 1 deiodinase; converts T4 to T3 | Affects local T3 supply for receptor binding |
| DIO2 | Type 2 deiodinase; converts T4 to T3 in target tissues | Critical for intracellular T3 generation |
| DIO3 | Type 3 deiodinase; inactivates T4 and T3 | Protects tissues from excess hormone |
| SLC16A2 | MCT8; thyroid hormone transporter | Mutations cause Allan-Herndon-Dudley syndrome |
| SLC16A10 | MCT10; thyroid hormone transporter | Facilitates cellular uptake of T4 and T3 |
| SLCO1C1 | OATP1C1; thyroid hormone transporter in brain | Important for brain thyroid hormone uptake |
| NCOA1 | Nuclear receptor coactivator 1; enhances TR-mediated transcription | Modulates thyroid hormone action after binding |
| NCOR1 | Nuclear receptor corepressor 1; represses unliganded TR | Regulates basal repression by TR |
| MED1 | Mediator complex subunit; bridges TR to transcription machinery | Required for T3-dependent transcription |
| RXRA | Retinoid X receptor alpha; heterodimer partner of TR | Essential for DNA binding and transcriptional regulation by TR |
| KDM5A | Histone demethylase; interacts with TR | Epigenetic regulator of thyroid hormone response |
| MIR22 | MicroRNA that targets thyroid hormone pathway components | Post-transcriptional regulation of thyroid hormone action |
How Is thyroid hormone binding Regulated?
Thyroid hormone binding is regulated at multiple levels. Hormone availability is controlled by the hypothalamic-pituitary-thyroid axis, where TSH stimulates thyroid hormone synthesis and release. Serum binding protein levels are influenced by estrogens, liver function, and genetic variants. Intracellularly, deiodinases (DIO1, DIO2, DIO3) modulate the conversion of T4 to T3 or inactive metabolites, thereby controlling ligand availability for receptor binding. MicroRNAs can repress the expression of thyroid hormone receptors and other pathway components, adding post-transcriptional control. Finally, post-translational modifications and cofactor recruitment regulate the transcriptional output of ligand-bound nuclear receptors.
thyroid hormone binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| THRB | Resistance to thyroid hormone (RTH) | Knock-in mouse or cell line with patient-derived THRB mutation |
| SERPINA7 | Inherited TBG deficiency or excess | CRISPR knockout of SERPINA7 in hepatocytes |
| TTR | Transthyretin amyloidosis and altered T4 transport | Knock-in of amyloidogenic TTR variants |
| SLC16A2 | Allan-Herndon-Dudley syndrome | Knockout of SLC16A2 in neuronal cells or organoids |
| CRYM | Sensorineural hearing loss and metabolic phenotypes | Crym knockout mouse model |
Resistance to thyroid hormone (RTH)
Resistance to thyroid hormone is most commonly caused by mutations in THRB that impair T3 binding to the receptor. Patients present with elevated thyroid hormone levels, non-suppressed TSH, and variable tissue-specific hypothyroidism or hyperthyroidism. The binding defect prevents normal negative feedback and target gene activation, illustrating the critical role of GO:0070324 in endocrine homeostasis.
Inherited serum thyroid hormone-binding protein mutations
Mutations in SERPINA7, TTR, and ALB can cause inherited euthyroid hyperthyroxinemia or hypothyroxinemia. These conditions are often asymptomatic but can lead to misdiagnosis and unnecessary treatment. They highlight the importance of serum binding in determining total hormone levels and the free hormone fraction.
Disorders of thyroid hormone transport
Mutations in the transporter SLC16A2 (MCT8) cause Allan-Herndon-Dudley syndrome, a severe X-linked neurodevelopmental disorder characterized by impaired thyroid hormone uptake into the brain. This demonstrates that binding and transport are coupled processes essential for brain development. Other transporters such as SLCO1C1 may also contribute to regional hormone delivery.
Thyroid hormone binding in cancer and metabolism
Altered expression of thyroid hormone receptors and binding proteins has been observed in various cancers and metabolic disorders. For example, THRB mutations and aberrant microRNA regulation can affect tumor cell proliferation and differentiation. While the exact mechanisms are context-dependent, the binding function remains a key node for therapeutic targeting.
From thyroid hormone binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene directly bind T3 or T4? | In vitro binding assay with recombinant protein and radiolabeled hormone |
| What is the effect of a patient mutation on hormone binding affinity? | Point-mutation knock-in cell line expressing mutant THRB |
| Which tissues require a specific binding protein for normal development? | Tissue-specific knockout mouse (e.g., CKO of Thrb in liver) |
| Can a novel binding protein be identified? | CRISPR library screening with T3-binding readout |
| How does overexpression of a binding protein affect hormone signaling? | Doxycycline-inducible overexpression cell line |
| What are the transcriptomic consequences of impaired binding? | RNA-seq of knockout vs wild-type cells treated with T3 |
How to Study the thyroid hormone binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Affinity (Kd) and capacity (Bmax) of T4/T3 binding | Characterizing mutant receptors or binding proteins |
| Surface plasmon resonance | Real-time binding kinetics (kon, koff) | Comparing wild-type and mutant binding proteins |
| X-ray crystallography | Three-dimensional structure of ligand-receptor complex | Understanding molecular basis of T3 binding |
| RNA-seq | Global changes in gene expression upon T3 treatment | Identifying thyroid hormone target genes |
| ChIP-seq | Genome-wide binding sites of thyroid hormone receptors | Mapping transcriptional regulatory elements |
| CRISPR knockout screen | Genes required for thyroid hormone binding or response | Discovery of novel pathway components |
| Proteomics | Protein interaction partners of binding proteins | Identifying cofactors and transporters |
| MicroRNA profiling | Expression of microRNAs regulating thyroid hormone action | Post-transcriptional regulation studies |
Binding assays
Radioligand binding assays using 125I-labeled T4 or T3 are the gold standard for measuring thyroid hormone binding affinity and capacity. These assays can be performed with recombinant proteins, cell lysates, or serum. Surface plasmon resonance and isothermal titration calorimetry provide kinetic and thermodynamic parameters.
Structural biology
X-ray crystallography and cryo-electron microscopy have revealed the atomic details of T3 binding to the ligand-binding domain of thyroid hormone receptors. These structures inform the design of selective modulators and explain the impact of disease-causing mutations.
Transcriptomics and epigenomics
RNA-seq and ChIP-seq can identify genes and regulatory elements controlled by thyroid hormone binding. Comparing wild-type and mutant cells or tissues reveals the transcriptional consequences of impaired binding. MicroRNA profiling adds another dimension of regulation.
CRISPR-based functional genomics
CRISPR knockout, knock-in, and point-mutation models allow precise testing of gene function in thyroid hormone binding. Pooled CRISPR screens can identify novel regulators of hormone uptake or receptor activity. These approaches are complemented by proteomics to map binding partners.
How CRISPR Can Be Used to Study GO:0070324 thyroid hormone binding
Knockout
CRISPR knockout of genes encoding thyroid hormone binding proteins (e.g., THRB, SERPINA7, CRYM) can abolish binding activity and reveal its physiological consequences. Knockout cell lines and mouse models are used to study hormone transport, feedback regulation, and target gene expression. These models are essential for validating candidate genes identified in screens.
Point Mutation
Introducing patient-specific point mutations (e.g., in THRB) via CRISPR base editing or homology-directed repair creates isogenic models that mimic disease alleles. These models allow precise measurement of binding affinity and transcriptional activity, providing mechanistic insights into resistance to thyroid hormone.
Knock-in
Knock-in of tagged versions of binding proteins (e.g., GFP-TRβ) enables live-cell imaging and proteomic analysis of hormone binding dynamics. Knock-in of reporter genes under thyroid hormone response elements allows monitoring of transcriptional output in real time.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of binding proteins can model states of hormone excess or altered binding capacity. Overexpression of CRYM, for example, can sequester T3 and modulate signaling. These models are useful for studying dose-dependent effects and for drug screening.
How EDITGENE Supports thyroid hormone binding Research
Researchers studying thyroid hormone binding-related genes often need to determine whether a candidate gene is causally involved in hormone transport, receptor activation, or disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for thyroid hormone binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TTR Knockout HEK293 Cell Line | EDJ-KQ1959 | Human | 7276 | Details Get a Quote |
| CTSH Knockout HEK293 Cell Line | EDJ-KQ2158 | Human | 1512 | Details Get a Quote |
| THRB Knockout HEK293 Cell Line | EDJ-KQ2592 | Human | 7068 | Details Get a Quote |
| THRA Knockout HEK293 Cell Line | EDJ-KQ2862 | Human | 7067 | Details Get a Quote |
| ALDH1A3 Knockout HEK293 Cell Line | EDJ-KQ4033 | Human | 220 | Details Get a Quote |
| CRYM Knockout HEK293 Cell Line | EDJ-KQ4359 | Human | 1428 | Details Get a Quote |
| THRB Knockout HCT 116 Cell Line | EDJ-KQ21921 | Human | 7068 | Details Get a Quote |
| ALDH1A3 Knockout HCT 116 Cell Line | EDJ-KQ25041 | Human | 220 | Details Get a Quote |
| CTSH Knockout A-549 Cell Line | EDJ-KQ22355 | Human | 1512 | Details Get a Quote |
| CTSH Knockout HCT 116 Cell Line | EDJ-KQ22356 | Human | 1512 | Details Get a Quote |
| CTSH Knockout HeLa Cell Line | EDJ-KQ22357 | Human | 1512 | Details Get a Quote |
| THRA Knockout A-549 Cell Line | EDJ-KQ22517 | Human | 7067 | Details Get a Quote |
| THRB Knockout A-549 Cell Line | EDJ-KQ23286 | Human | 7068 | Details Get a Quote |
| THRA Knockout HCT 116 Cell Line | EDJ-KQ23886 | Human | 7067 | Details Get a Quote |
| THRA Knockout HeLa Cell Line | EDJ-KQ23887 | Human | 7067 | Details Get a Quote |
Displaying Records 1 To 15 Of 24 Records
Frequently Asked Questions About thyroid hormone binding
What is GO:0070324 thyroid hormone binding?
GO:0070324 is a Gene Ontology molecular function term that describes the binding of a protein to thyroxine (T4) or triiodothyronine (T3), the hormones produced by the thyroid gland.
What genes are involved in thyroid hormone binding?
Key genes include THRA, THRB, SERPINA7, TTR, ALB, CRYM, and transporters such as SLC16A2.
What diseases are associated with defective thyroid hormone binding?
Mutations in THRB cause resistance to thyroid hormone, while mutations in SERPINA7, TTR, and ALB cause inherited euthyroid hyperthyroxinemia or hypothyroxinemia.
How is thyroid hormone binding measured in the lab?
Common methods include radioligand binding assays, surface plasmon resonance, and isothermal titration calorimetry using recombinant proteins or cell lysates.
What is the difference between T3 and T4 binding?
T3 is the more biologically active hormone and binds nuclear receptors with higher affinity than T4; both are transported by serum proteins but with different affinities.
Can CRISPR be used to study thyroid hormone binding?
Yes, CRISPR knockout, knock-in, and point-mutation models allow precise manipulation of genes encoding binding proteins to study their function and disease relevance.
What is µ-crystallin and how does it relate to thyroid hormone binding?
µ-Crystallin (CRYM) is an intracellular T3-binding protein that modulates hormone availability and has been linked to hearing and metabolic phenotypes.
How do mutations in thyroid hormone receptors cause disease?
Mutations in THRB that impair T3 binding prevent normal transcriptional regulation, leading to resistance to thyroid hormone with elevated hormone levels and tissue-specific symptoms.
What are the research methods for studying thyroid hormone binding?
Methods include binding assays, structural biology (crystallography/cryo-EM), transcriptomics, proteomics, and CRISPR-based functional genomics.
Why is thyroid hormone binding important for brain development?
Thyroid hormones must be transported into the brain and bind to neuronal receptors to regulate gene expression essential for myelination and neuronal differentiation; defects cause severe neurodevelopmental disorders.
Conclusion
Thyroid hormone binding (GO:0070324) is a fundamental molecular function that governs the transport, cellular uptake, and nuclear action of T4 and T3. It is mediated by a network of serum carriers, transporters, intracellular binding proteins, and nuclear receptors, and its disruption leads to a range of endocrine and neurodevelopmental disorders. Understanding the precise mechanisms of thyroid hormone binding is essential for diagnosing and treating related diseases. Modern CRISPR-based models and high-throughput methods provide powerful tools to dissect this function at molecular resolution.
References
- 1. Carvalho DP et al.. 2017. Thyroid hormone biosynthesis and release.. Mol Cell Endocrinol 458:6-15 PMID: 28153798
- 2. Kinney CJ et al.. 2021. µ-Crystallin: A thyroid hormone binding protein.. Endocr Regul 55(2):89-102 PMID: 34020530
- 3. Tambones I et al.. 2024. Structural Insights Into Thyroid Hormone Receptors.. Endocrinology 166(1) PMID: 39541421
- 4. Mimoto MS et al.. 2020. Clinical recognition and evaluation of patients with inherited serum thyroid hormone-binding protein mutations.. J Endocrinol Invest 43(1):31-41 PMID: 31352644
- 5. Lazar MA. 2003. Thyroid hormone action: a binding contract.. J Clin Invest 112(4):497-9 PMID: 12925689
- 6. Braun D et al.. 2018. Thyroid Hormone Transport and Transporters.. Vitam Horm 106:19-44 PMID: 29407435
- 7. Aranda A. 2021. MicroRNAs and thyroid hormone action.. Mol Cell Endocrinol 525:111175 PMID: 33515639
- 8. Weiss RE et al.. 1992. Thyroid hormone resistance.. Annu Rev Med 43:363-75 PMID: 1580595
